CIRCULAR HEALTHCARE · ARTICLE 17 · JUST TRANSITION
Reprocessing Single-Use Medical Devices (SUMD) Under EU MDR Article 17
Single-use medical devices are labelled for one use, yet many can be safely cleaned, tested and used again under strict rules. This article explains the law, the evidence, the current European picture and the Global South questions that follow.
What is SUMD reprocessing?
Reprocessing a single-use medical device (SUMD) means collecting a device after use and putting it through a validated cycle of cleaning, testing, sterilisation and inspection so that it can safely be used again. It is not informal reuse: the work is done by a certified reprocessor or a qualified hospital unit that takes on the legal responsibilities of a manufacturer for the reprocessed device.
The point is simple. A device that is used once and thrown away carries the full cost and full environmental burden of manufacture, transport and disposal. A device that is safely used two or three times spreads that burden across several uses.
What EU MDR Article 17 actually says
Article 17 is the part of the European Union Medical Device Regulation that sets the rules for reprocessing single-use medical devices. It allows the practice only where a country’s national law permits it, and it requires strict safety, quality and legal responsibility. Implementing Regulation (EU) 2020/1207 sets out the common specifications reprocessors must meet.
This creates a two-key system. The EU sets the safety floor; each member state decides whether reprocessing is allowed at all on its territory, and by which pathway — a certified external reprocessor, in-hospital reprocessing, or both.
Permission is not the same as uptake
Permission means the law allows reprocessing. Uptake means hospitals, reprocessors and certification bodies are actually using the system in practice. Europe currently has much more permission than real activity.
In the Commission’s reporting period of December 2022 to December 2023, ten of thirty study countries allowed reprocessing. Only six of thirty-eight surveyed notified bodies offered certification, and no certificates were reported in that period. Fewer than ten manufacturers were identified, with only two active and operating in the EU.
Three things explain the gap. Hospitals need trained teams, safe systems, time and funding. Approvals are limited, because only a small number of organisations offer the required certification. And where law does permit the practice — the Netherlands, for example, with Amsterdam simply following national Dutch rules — capacity still has to be built before anything changes on the ward.
You can see the full country picture, including permitted methods and ratification status, on the EU uptake dashboard.
What wider reprocessing could change
Four effects follow from displacing new-device purchases. Hospitals buy fewer new devices, which lowers procurement spend. Device mass is retained in use rather than becoming clinical waste. Manufacturing emissions are avoided, with an illustrative average of about 44 percent reduction versus a new device in the scenario default. And demand for newly mined metals and minerals may fall, though that link must still be verified through supply-chain data.
The impact model lets you set eligible device uses, reprocessing cycles, device mass, new-device price, reprocessed discount and GHG reduction, and see all four outputs update together.
The Global South and mineral justice
Medical devices contain metals and minerals whose extraction concentrates in producing countries across Africa, Latin America and Asia. If fewer new devices are made, manufacturers may need fewer newly mined materials — but the communities carrying the environmental and social cost of extraction do not automatically benefit.
That is why the dashboard pairs an exposure screen with an optional just-transition allocation: a share of estimated hospital savings that could be invested in mine remediation, worker protection, alternative livelihoods, supply-chain traceability or regional reprocessing capacity. Reprocessing one device does not stop a specific mine. The honest claim is about direction of demand and where reinvestment could go.
Limitations you should read before quoting figures
Regulatory data reflect the Commission’s Article 17 report and later national notifications, so they can lag a country’s current position. Environmental evidence is device-specific and heterogeneous; a 2026 systematic review rated safety and cost certainty very low. Social and mineral-justice indicators are exposure screens until supplier traceability is obtained. Every number on this site is a modelled estimate, not a measured result.